Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021. Issue 8 (21st November 2021)

• Record Type: Journal Article
• Authors: Dargaud, Yesim; Escuriola‐Ettingshausen, Carmen
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 5:Issue 8(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-11-21
• Subjects: anti‐factor VIII antibodies -- acquired Hemophilia A -- porcine factor VIII hereditary; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12631
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII products. Bypassing agents to control bleeding episodes are recommended for these patients, but their efficacy is difficult to predict and monitor. FVIII products derived from porcine plasma had an important role in the treatment of hemophilia A for 50 years, from 1954 to 2004. Indeed, porcine FVIII could achieve hemostasis in patients in whom human FVIII products were ineffective. A recombinant porcine FVIII product is now available. This highly purified protein has the same biochemical and hemostatic properties, but much lower risks of infection and toxicity compared with plasma‐derived porcine FVIII. The product is licensed in the United States and Europe for the treatment of acquired hemophilia A. However, this recombinant molecule could also be of clinical interest for people with inherited hemophilia A and inhibitors, particularly for the management of bleeding episodes in people receiving emicizumab as prophylactic treatment in the absence of anti‐porcine FVIII antibodies.